ライフサイエンスコーパス: ledipasvir

1 evir, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir.

2 rring resistance to NS5A inhibitors, such as ledipasvir.

3 sofosbuvir combined with the NS5A inhibitor ledipasvir.

4 S-9451) and after 12 weeks with sofosbuvir + ledipasvir.

5 and gt4r, which respond poorly to sofosbuvir/ledipasvir.

6 2 subtypes, gt1l and gt4r, using sofosbuvir/ledipasvir.

7 : sofosbuvir/velpatasvir (27.3%), sofosbuvir/ledipasvir (26.5%), grazoprevir/elbasvir (12.5%), other

8 treatment groups: 12 weeks of sofosbuvir and ledipasvir; 6 weeks of sofosbuvir, ledipasvir, and GS-96

9 b infection who received the combination of ledipasvir (90 mg) and sofosbuvir (400 mg) (ledipasvir/s

10 We gave patients 12 weeks of ledipasvir (90 mg) and sofosbuvir (400 mg) as a single c

11 reater were randomly assigned 1:1 to receive ledipasvir (90 mg) and sofosbuvir (400 mg) for 12 or 24

12 reater were randomly assigned 1:1 to receive ledipasvir (90 mg) and sofosbuvir (400 mg) for 12 or 24

13 All participants were given ledipasvir (90 mg) and sofosbuvir (400 mg) in a single c

14 sation sequence to receive 12 or 24 weeks of ledipasvir (90 mg) and sofosbuvir (400 mg) once daily (c

15 were prescribed a fixed-dose combination of ledipasvir (90 mg) and sofosbuvir (400 mg) once daily fo

16 re randomly assigned (1:1) to receive either ledipasvir (90 mg) and sofosbuvir (400 mg) or ledipasvir

17 fosbuvir (400 mg) and the HCV NS5A inhibitor ledipasvir (90 mg), with and without ribavirin--in patie

18 hat the fixed-dose combination of sofosbuvir-ledipasvir alone or with ribavirin has the potential to

19 All patients received ledipasvir, an NS5A inhibitor, and sofosbuvir, a nucleot

20 a fixed-dose combination tablet of 90 mg of ledipasvir and 400 mg of sofosbuvir orally once-daily fo

21 years received a combination tablet of 90 mg ledipasvir and 400 mg sofosbuvir once daily for 12 weeks

22 ven a fixed-dose combination tablet of 90 mg ledipasvir and 400 mg sofosbuvir orally once per day for

23 aily combination fixed-dose tablets of 90 mg ledipasvir and 400 mg sofosbuvir plus weight-based ribav

24 eeks of anti-HCV treatment using sofosbuvir, ledipasvir and a non-nucleoside polymerase-inhibitor (GS

25 went antiviral therapy (AVT) with sofosbuvir/ledipasvir and chemotherapy (14 rituximab plus cyclophos

26 pan-genotypic anti-HCV activity compared to ledipasvir and daclatasvir.

27 stances where accurate genotyping is absent, ledipasvir and its generic compounds should not be consi

28 single-tablet regimen of the NS5A inhibitor ledipasvir and NS5B nucleotide polymerase inhibitor sofo

29 ir for 12 weeks (group 4) or sofosbuvir plus ledipasvir and ribavirin for 12 weeks (group 5).

30 asvir for 8 weeks (group 1), sofosbuvir plus ledipasvir and ribavirin for 8 weeks (group 2), or sofos

31 usly demonstrated that adding a third DAA to ledipasvir and sofosbuvir (LDV/SOF) can result in high S

32 We assessed PROs in patients treated with ledipasvir and sofosbuvir (LDV/SOF) with and without RBV

33 ype 1 infection without cirrhosis to receive ledipasvir and sofosbuvir (ledipasvir-sofosbuvir) for 8

34 roups given fixed-dose combination tablet of ledipasvir and sofosbuvir (n = 25) or ledipasvir and sof

35 enotype 3 patients, 16 of 25 (64%) receiving ledipasvir and sofosbuvir alone achieved SVR12 compared

36 let of ledipasvir and sofosbuvir (n = 25) or ledipasvir and sofosbuvir along with ribavirin (n = 26).

37 r treatment (SVR12) with regimens containing ledipasvir and sofosbuvir and identify factors associate

38 mpared with all 26 patients (100%) receiving ledipasvir and sofosbuvir and ribavirin.

39 tients with HCV genotype 3 (n = 50) received ledipasvir and sofosbuvir and ribavirin.

40 Regimens containing ledipasvir and sofosbuvir are highly effective for a bro

41 One patient with HCV genotype 3 discontinued ledipasvir and sofosbuvir because of an adverse event (d

42 Thirteen patients (4%) discontinued the ledipasvir and sofosbuvir combination prematurely becaus

43 afety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this populatio

44 Ledipasvir and sofosbuvir for 12 weeks provided high rat

45 IV, administration of an oral combination of ledipasvir and sofosbuvir for 12 weeks was associated wi

46 lity of 12 weeks of combination therapy with ledipasvir and sofosbuvir for patients with chronic HCV

47 The combination of ledipasvir and sofosbuvir has been approved for treatmen

48 ents with HCV genotype 1, the combination of ledipasvir and sofosbuvir has been shown to cure high pr

49 domly assigned in a 1:1:1:1 ratio to receive ledipasvir and sofosbuvir in a fixed-dose combination ta

50 The all-oral regimen of ledipasvir and sofosbuvir is an effective and safe treat

51 ants received a 3-drug regimen consisting of ledipasvir and sofosbuvir plus GS-9451 for 4 weeks, and

52 te the safety, tolerability, and efficacy of ledipasvir and sofosbuvir plus ribavirin in patients wit

53 enotype 3 infection who received 12 weeks of ledipasvir and sofosbuvir plus ribavirin, and by patient

54 with a once-daily, single-tablet regimen of ledipasvir and sofosbuvir resulted in high rates of sust

55 ir fixed-dose combination tablets [Epclusa], ledipasvir and sofosbuvir tablets [Harvoni], insulin lis

56 Ledipasvir and sofosbuvir treatment for 12 weeks was wel

57 Sofosbuvir with ledipasvir and sofosbuvir with ribavirin have received r

58 f a fixed-dose combination tablet containing ledipasvir and sofosbuvir, once daily, plus ribavirin.

59 trial to evaluate the efficacy and safety of ledipasvir and sofosbuvir, with or without ribavirin, in

60 rrent guidelines do not recommend the use of ledipasvir and sofosbuvir, with or without ribavirin, in

61 ons (RASs) on response to the combination of ledipasvir and sofosbuvir, with or without ribavirin, in

62 tients with HCV genotype 6 (n = 25) received ledipasvir and sofosbuvir.

63 ed with adults from phase 2 and 3 studies of ledipasvir and sofosbuvir.

64 tion of the hepatitis C virus NS5A inhibitor ledipasvir and the NS5B nucleotide polymerase inhibitor

65 combination therapy with the NS5A inhibitor ledipasvir and the NS5B polymerase inhibitor sofosbuvir

66 he efficacy and safety of the NS5A inhibitor ledipasvir and the nucleotide polymerase inhibitor sofos

67 domly assigned to receive the NS5A inhibitor ledipasvir and the nucleotide polymerase inhibitor sofos

68 [17%] of six patients receiving sofosbuvir, ledipasvir, and asunaprevir; one [17%] of six patients r

69 12 patients were assigned to sofosbuvir, ledipasvir, and asunaprevir; six to sofosbuvir, daclatas

70 o one of three treatment groups (sofosbuvir, ledipasvir, and asunaprevir; sofosbuvir, daclatasvir, an

71 notype 3a was less sensitive to daclatasvir, ledipasvir, and elbasvir, but equally sensitive to ombit

72 maximum concentration values for sofosbuvir, ledipasvir, and GS-331007 were within the predefined pha

73 GS-9669 for 6 weeks (n = 20), or sofosbuvir, ledipasvir, and GS-9451 for 6 weeks (n = 19).

74 of the 20 patients allocated to sofosbuvir, ledipasvir, and GS-9451 for 6 weeks (one patient was los

75 svir, and GS-9669; or 6 weeks of sofosbuvir, ledipasvir, and GS-9451.

76 edipasvir for 12 weeks (n = 20), sofosbuvir, ledipasvir, and GS-9669 for 6 weeks (n = 20), or sofosbu

77 of the 20 patients allocated to sofosbuvir, ledipasvir, and GS-9669 for 6 weeks (one patient relapse

78 buvir and ledipasvir; 6 weeks of sofosbuvir, ledipasvir, and GS-9669; or 6 weeks of sofosbuvir, ledip

79 luation of the concentrations of sofosbuvir, ledipasvir, and the sofosbuvir metabolite GS-331007.

80 ovir alafenamide, emtricitabine, sofosbuvir, ledipasvir, and velpatasvir were inactive at concentrati

81 paritaprevir/ritonavir/dasabuvir; sofosbuvir/ledipasvir; and daclatasvir/sofosbuvir, respectively, to

82 sofosbuvir+ribavirin; US$192 for sofosbuvir+ledipasvir; and US$115 for MK-8742+MK-5172.

83 Daclatasvir and ledipasvir belong to the NS5A inhibitor class, which dir

84 as associated with failure of daclatasvir or ledipasvir, but not ombitasvir.

85 the half-maximal effective concentration to ledipasvir by more than 100-fold reduced the rate of SVR

86 According to the label, sofosbuvir and ledipasvir can be prescribed for 8 weeks (SL8) in noncir

87 py with the nonstructural (NS) 5A inhibitor, ledipasvir, combined with the NS5B polymerase inhibitor,

88 Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based ther

89 ing sofosbuvir, simeprevir, daclatasvir, and ledipasvir cost $7000, $5500, $5500, and $875 per week,

90 Resistance to daclatasvir and ledipasvir differs from alisporivir, with mutations aris

91 aclatasvir, but no RASs were associated with ledipasvir failure, pointing to a limited efficacy of le

92 in for 8 weeks (group 2), or sofosbuvir plus ledipasvir for 12 weeks (group 3).

93 inhibitor regimen to receive sofosbuvir plus ledipasvir for 12 weeks (group 4) or sofosbuvir plus led

94 avirin for 24 weeks (n = 55), sofosbuvir and ledipasvir for 12 weeks (n = 20), sofosbuvir, ledipasvir

95 All 14 patients treated with sofosbuvir plus ledipasvir for 12 weeks achieved a sustained virologic r

96 atients who achieved SVR with Sofosbuvir and Ledipasvir for 12 weeks and compared with 15 healthy con

97 4 weeks were re-treated with sofosbuvir plus ledipasvir for 12 weeks.

98 , 95% CI 83-100) allocated to sofosbuvir and ledipasvir for 12 weeks; in 19 (95%, 75-100) of the 20 p

99 nt-naive patients to receive sofosbuvir plus ledipasvir for 8 weeks (group 1), sofosbuvir plus ledipa

100 pid response were switched to sofosbuvir and ledipasvir for either 8 weeks or 12 weeks.

101 + ribavirin (HCV genotype 2) or sofosbuvir + ledipasvir (genotype 1 or 4) and retreatment with sofosb

102 acokinetics led to the identification of 39 (ledipasvir, GS-5885).

103 ed SVR rates it was necessary to assume that ledipasvir, GS-9669 and GS-9451 rapidly reduce virus inf

104 RBV in 30, SOF + simeprevir in 11, and SOF + ledipasvir in 23.

105 vir/daclatasvir in 36.8%, and for sofosbuvir/ledipasvir in 40.2%.

106 rventional study, which evaluated sofosbuvir/ledipasvir in 8 pregnant individuals.

107 r failure, pointing to a limited efficacy of ledipasvir in patients with genotype 3.

108 ed the efficacy and safety of sofosbuvir and ledipasvir in renal transplant patients with chronic HCV

109 valuated the effectiveness of sofosbuvir and ledipasvir in treatment-naive and treatment-experienced

110 and P7977-2025) and 5 studies of combination ledipasvir (LDV) and SOF (LDV/SOF; LONESTAR, ELECTRON [L

111 ve was to identify drug interactions between ledipasvir (LDV) and sofosbuvir (SOF) against a genotype

112 tudy, we assessed the efficacy and safety of ledipasvir (LDV) and sofosbuvir (SOF) for 12 weeks in HC

113 tor sofosbuvir (SOF) with the NS5A inhibitor ledipasvir (LDV) or the NS5B non-nucleoside inhibitor GS

114 nt, particularly the use of sofosbuvir (SOF)/ledipasvir (LDV) without RBV in this patient population.

115 f the nonstructural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease inhibitor vedroprevir (VD

116 l trial to assess the efficacy and safety of ledipasvir (LDV)-SOF plus RBV in patients with genotype

117 We evaluated the safety and efficacy of ledipasvir (LDV)-sofosbuvir (SOF) in treating HCV genoty

118 Ledipasvir (LDV)/sofosbuvir (SOF) has demonstrated high

119 ost commonly used regimen was sofosbuvir and ledipasvir (n = 21).

120 + RBV, n = 25; SOF + RBV, n = 36; and SOF + ledipasvir, n = 6) between January and November 2014.

121 of different concentrations of daclatasvir, ledipasvir, ombitasvir, elbasvir, ruzasvir, velpatasvir,

122 dy, direct-acting antiviral therapy with SOF/ledipasvir, ombitasvir/paritaprevir/ritonavir + dasabuvi

123 We compared using sofosbuvir/ledipasvir or ombitasvir/ritonavir/paritaprevir/dasabuvi

124 dasabuvir, or combinations of sofosbuvir and ledipasvir or sofosbuvir and velpatasvir had decreased e

125 ntly associated with failure of daclatasvir, ledipasvir, or ombitasvir in patients with genotype 1b i

126 ed interferon and ribavirin, sofosbuvir plus ledipasvir, or sofosbuvir plus ribavirin for 12 weeks ar

127 fosbuvir and an NS5A inhibitor (daclatasvir, ledipasvir, or velpatasvir), 5 (38.5%) also harbored NS5

128 inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic

129 type) and were treated with sofosbuvir (SOF)/ledipasvir +/- ribavirin (85%) followed by SOF + daclata

130 irin, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir-ribavirin (genotype 3 only).

131 For genotype 3, sofosbuvir-ledipasvir-ribavirin cost $73 000 per QALY, sofosbuvir-r

132 For genotype 3, sofosbuvir-ledipasvir-ribavirin would be cost-saving if sofosbuvir

133 tasvir (sovodak) plus ivermectin, sofosbuvir/ledipasvir (SOF/LED) plus hydroxychloroquine, and SOF/LE

134 , for genotype 1 infections, sofosbuvir plus ledipasvir, sofosbuvir plus daclatasvir, or ombitasvir,

135 edipasvir (90 mg) and sofosbuvir (400 mg) or ledipasvir, sofosbuvir, and ribavirin (dosed according t

136 The combination of ledipasvir, sofosbuvir, and ribavirin for 12 weeks produ

137 We assessed the safety and efficacy of ledipasvir, sofosbuvir, and ribavirin in patients with H

138 d 25 received a 4-drug regimen consisting of ledipasvir, sofosbuvir, GS-9451, and GS-9669 for 4 weeks

139 e analyzed data from 1788 patients receiving ledipasvir-sofosbuvir (282 for 8 weeks, 910 for 12 weeks

140 All patients were treated with ledipasvir-sofosbuvir (90 mg and 400 mg) plus weight-bas

141 received a fixed-dose combination tablet of ledipasvir-sofosbuvir (90/400 mg) once daily for 12 week

142 nd 88 of 88 treatment experienced) receiving ledipasvir-sofosbuvir (95% CI 98-100) and 167 (98%) of 1

143 Across 11 phase 3 clinical trials of ledipasvir-sofosbuvir (SOF) and SOF, only 12 of 3004 pat

144 5%] of 170), and headache in those receiving ledipasvir-sofosbuvir and ribavirin (15 [8.8%] of 170).

145 Ledipasvir-sofosbuvir and ribavirin provided high rates

146 100) in the group that received 24 weeks of ledipasvir-sofosbuvir and ribavirin.

147 o 99) in the group that received 12 weeks of ledipasvir-sofosbuvir and ribavirin; 99% (95% CI, 95 to

148 = 1) received weight-based doses of combined ledipasvir-sofosbuvir as granules (33.75 mg/150 mg for w

149 coinfected kidney transplant recipients with ledipasvir-sofosbuvir at our 2 centers.

150 hronic HCV genotype 1 infection; the dose of ledipasvir-sofosbuvir currently used in adults was well

151 No patient who received 8 weeks of only ledipasvir-sofosbuvir discontinued treatment owing to ad

152 Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks was well-tolera

153 Conclusion: Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks was well-tolera

154 r treatment-naive and -experienced patients, ledipasvir-sofosbuvir for 12 weeks is highly effective f

155 ir-sofosbuvir plus ribavirin for 8 weeks, or ledipasvir-sofosbuvir for 12 weeks.

156 r-sofosbuvir plus ribavirin for 12 weeks and ledipasvir-sofosbuvir for 24 weeks provided similarly hi

157 svir-sofosbuvir plus ribavirin for 12 weeks, ledipasvir-sofosbuvir for 24 weeks, or ledipasvir-sofosb

158 svir-sofosbuvir plus ribavirin for 12 weeks, ledipasvir-sofosbuvir for 24 weeks, or ledipasvir-sofosb

159 s were achieved by 96% of patients receiving ledipasvir-sofosbuvir for 8 weeks (95% CI, 93%-98%), 97%

160 Ledipasvir-sofosbuvir for 8 weeks was associated with a

161 sessed the efficacy and safety of 6 weeks of ledipasvir-sofosbuvir for acute genotype 1 or 4 HCV in H

162 was to establish the safety and efficacy of ledipasvir-sofosbuvir for chronic HCV genotype 1 or 4 in

163 ate of cure with a fixed-dose combination of ledipasvir-sofosbuvir for patients with acute genotype 1

164 plus ribavirin group and 97% (91-100) in the ledipasvir-sofosbuvir group.

165 study to evaluate the efficacy and safety of ledipasvir-sofosbuvir in adolescents with chronic HCV ge

166 erefore evaluated the safety and efficacy of ledipasvir-sofosbuvir in HCV-infected children aged 3 to

167 f the interferon- and ribavirin-free regimen ledipasvir-sofosbuvir in kidney transplant recipients wi

168 f the interferon- and ribavirin-free regimen ledipasvir-sofosbuvir in kidney transplant recipients wi

169 trial to evaluate the safety and efficacy of ledipasvir-sofosbuvir in Rwandan adults with chronic HCV

170 The oral regimen of ledipasvir-sofosbuvir is an effective and well-tolerated

171 Ledipasvir-sofosbuvir is effective at eradicating hepati

172 All patients received ledipasvir-sofosbuvir once daily for 6 weeks.

173 quentially assigned to either treatment with ledipasvir-sofosbuvir or ledipasvir-sofosbuvir plus riba

174 patient in either 12-week group discontinued ledipasvir-sofosbuvir owing to an adverse event.

175 plus weight-based ribavirin for 12 weeks, or ledipasvir-sofosbuvir plus placebo once daily for 24 wee

176 for a different duration) and 311 receiving ledipasvir-sofosbuvir plus ribavirin (212 for 12 weeks a

177 nd 87 of 87 treatment experienced) receiving ledipasvir-sofosbuvir plus ribavirin (95% CI 95-100).

178 d randomisation, 77 were assigned to receive ledipasvir-sofosbuvir plus ribavirin and 78 ledipasvir-s

179 Ledipasvir-sofosbuvir plus ribavirin for 12 weeks and le

180 combination tablet once daily for 12 weeks, ledipasvir-sofosbuvir plus ribavirin for 12 weeks, ledip

181 fixed-dose combination tablet for 12 weeks, ledipasvir-sofosbuvir plus ribavirin for 12 weeks, ledip

182 eeks, ledipasvir-sofosbuvir for 24 weeks, or ledipasvir-sofosbuvir plus ribavirin for 24 weeks.

183 eeks, ledipasvir-sofosbuvir for 24 weeks, or ledipasvir-sofosbuvir plus ribavirin for 24 weeks.

184 osbuvir (ledipasvir-sofosbuvir) for 8 weeks, ledipasvir-sofosbuvir plus ribavirin for 8 weeks, or led

185 were 96% (95% CI 89-99) for patients in the ledipasvir-sofosbuvir plus ribavirin group and 97% (91-1

186 Two (1.2%) of 170 patients in the ledipasvir-sofosbuvir plus ribavirin group discontinued

187 ther treatment with ledipasvir-sofosbuvir or ledipasvir-sofosbuvir plus ribavirin in a 1:1 ratio with

188 uvir, 93% (95% CI, 89 to 96) with 8 weeks of ledipasvir-sofosbuvir plus ribavirin, and 95% (95% CI, 9

189 100) in the group that received 24 weeks of ledipasvir-sofosbuvir plus ribavirin.

190 o 99) in the group that received 12 weeks of ledipasvir-sofosbuvir plus ribavirin; 98% (95% CI, 95 to

191 Seven patients (2%) discontinued ledipasvir-sofosbuvir prematurely due to adverse events.

192 ve patients with genotype 3 HCV, 12 weeks of ledipasvir-sofosbuvir provided a high level of SVR in th

193 sults indicated noninferiority of the 8-week ledipasvir-sofosbuvir regimen, on the basis of a noninfe

194 ty, and absence of drug-drug interactions of ledipasvir-sofosbuvir suggest that it could be an import

195 dosing required adjustment during and after ledipasvir-sofosbuvir therapy but antiretroviral regimen

196 Ledipasvir-sofosbuvir was highly effective at treating a

197 atment, a second cohort receiving 8 weeks of ledipasvir-sofosbuvir was to be enrolled.

198 Conclusion: Ledipasvir-sofosbuvir was well tolerated and highly effe

199 Ledipasvir-sofosbuvir was well tolerated.

200 The single patient receiving 12 weeks of ledipasvir-sofosbuvir who did not reach SVR12 did not co

201 Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 o

202 e rate in the group that received 8 weeks of ledipasvir-sofosbuvir with ribavirin was 1 percentage po

203 rhosis to receive ledipasvir and sofosbuvir (ledipasvir-sofosbuvir) for 8 weeks, ledipasvir-sofosbuvi

204 nce interval [CI], 90 to 97) with 8 weeks of ledipasvir-sofosbuvir, 93% (95% CI, 89 to 96) with 8 wee

205 sponse in the group that received 8 weeks of ledipasvir-sofosbuvir, the rate in the 12-week group was

206 Patients received treatment with ledipasvir-sofosbuvir, which was provided on site, accor

207 l patients who received at least one dose of ledipasvir-sofosbuvir.

208 ug-related treatment discontinuations due to ledipasvir-sofosbuvir.

209 ledipasvir-sofosbuvir plus ribavirin and 78 ledipasvir-sofosbuvir.

210 and 95% (95% CI, 92 to 98) with 12 weeks of ledipasvir-sofosbuvir.

211 gic response at 12 weeks after completion of ledipasvir-sofosbuvir.

212 o 97) in the group that received 12 weeks of ledipasvir-sofosbuvir; 96% (95% CI, 91 to 99) in the gro

213 100) in the group that received 12 weeks of ledipasvir-sofosbuvir; 97% (95% CI, 94 to 99) in the gro

214 100) in the group that received 24 weeks of ledipasvir-sofosbuvir; and 99% (95% CI, 95 to 100) in th

215 o 99) in the group that received 24 weeks of ledipasvir-sofosbuvir; and 99% (95% CI, 97 to 100) in th

216 e (nine [5.3%] of 171) in patients receiving ledipasvir-sofosbuvir; and nasopharyngitis (40 [23.5%] o

217 atment options included sofosbuvir (SOF) and ledipasvir/sofosbuvir (LDV/SOF) based regimens.

218 Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in gen

219 The uptake of ledipasvir/sofosbuvir (LDV/SOF) regimens across health c

220 /ritonavir, ombitasvir, dasabuvir (PrOD) and ledipasvir/sofosbuvir (LDV/SOF) regimens upon mortality.

221 g, and with health insurance likely to cover ledipasvir/sofosbuvir (LDV/SOF) were recruited from 34 U

222 the ION-4 study, black patients treated with ledipasvir/sofosbuvir (LDV/SOF) were significantly less

223 once-daily fixed-dose combination tablet of ledipasvir/sofosbuvir (LDV/SOF) with and without ribavir

224 SVR) for patients taking concomitant PPI and ledipasvir/sofosbuvir (LDV/SOF).

225 ofosbuvir/velpatasvir (SOF/VEL; n = 54), and ledipasvir/sofosbuvir (LDV/SOF; n = 145).

226 began treatment with sofosbuvir (n = 2986), ledipasvir/sofosbuvir (n = 11,327), or PrOD (n = 3174),

227 ks of daclatasvir plus sofosbuvir (n = 767), ledipasvir/sofosbuvir (n = 197), or sofosbuvir/velpatasv

228 eved an SVR12 to 12 weeks (but not 24 weeks) ledipasvir/sofosbuvir (P < .001).

229 tudies evaluated a fixed-dose combination of ledipasvir/sofosbuvir +/- ribavirin administered for 8,

230 ed virologic response (SVR12), and safety of ledipasvir/sofosbuvir +/- ribavirin.

231 eeks after the end of treatment (SVR12) with ledipasvir/sofosbuvir and only a small effect in patient

232 infection (no significant difference between ledipasvir/sofosbuvir and PrOD regimens), 86.2% (95% CI,

233 e of SVR12 in treatment-naive patients given ledipasvir/sofosbuvir for 8 weeks (P = .011), but not fo

234 ter clinical trial, investigating 8 weeks of ledipasvir/sofosbuvir for acute HCV infections in men wi

235 sessed the safety and efficacy of 8 weeks of ledipasvir/sofosbuvir for the treatment of acute HCV inf

236 Approval of Ledipasvir/Sofosbuvir for the treatment of chronic hepat

237 y was to evaluate the safety and efficacy of ledipasvir/sofosbuvir in black patients using data from

238 se RASs had a small effect in patients given ledipasvir/sofosbuvir in combination with ribavirin for

239 An 8-week regimen of ledipasvir/sofosbuvir is effective for eligible patients

240 Short 8-week ledipasvir/sofosbuvir monotherapy regimens should perhap

241 ng genotype 1-infected patients treated with ledipasvir/sofosbuvir monotherapy, black patients had si

242 We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 h

243 enotype 3 infection (77.9% in patients given ledipasvir/sofosbuvir plus ribavirin, 87.0% in patients

244 Eight-week regimens of ledipasvir/sofosbuvir produced an SVR12 in 94.3% of elig

245 have minimal effects on patient responses to ledipasvir/sofosbuvir therapy.

246 We evaluated the relationship between ledipasvir/sofosbuvir treatment persistence (receiving 8

247 A once-daily dosage of ledipasvir/sofosbuvir was similarly effective in black a

248 We examined the effectiveness of ledipasvir/sofosbuvir with or without ribavirin (LDV/SOF

249 afety and efficacy of 8, 12, and 24 weeks of ledipasvir/sofosbuvir with or without ribavirin for the

250 ledipasvir (90 mg) and sofosbuvir (400 mg) (ledipasvir/sofosbuvir) once daily, with or without ribav

251 is study was to model the impact of LDV/SOF (ledipasvir/sofosbuvir), the first Peg-IFN- and RBV-free

252 sofosbuvir, 97.9% (95% CI, 94.8-99.2%) with ledipasvir/sofosbuvir, and 96.5% (95% CI, 88.1-99.0%) wi

253 the real-world effectiveness of sofosbuvir, ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombita

254 actice setting, daclatasvir plus sofosbuvir, ledipasvir/sofosbuvir, and sofosbuvir/velpatasvir achiev

255 l patients received genotype-guided DAAs: 17 ledipasvir/sofosbuvir, eight sofosbuvir plus ribavirin,

256 taining sofosbuvir, simeprevir + sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ombitasvir/ritona

257 le treatment options included sofosbuvir and ledipasvir/sofosbuvir-based regimens.

258 ents who cleared HCV with a 6-week course of ledipasvir/sofosbuvir.

259 d after receiving 12 weeks of treatment with ledipasvir/sofosbuvir.

260 e assessed treatment with the NS5A inhibitor ledipasvir, the nucleotide polymerase inhibitor sofosbuv

261 and $875 per week, respectively, sofosbuvir-ledipasvir was cost-effective for genotype 1 and cost $1

262 he fixed-dose combination of sofosbuvir plus ledipasvir was efficacious in a small cohort of patients

263 Sofosbuvir-ledipasvir was the optimal strategy in most simulations

264 Sofosbuvir plus ledipasvir was well-tolerated with few adverse events.

265 Sofosbuvir and ledipasvir, which have recently been approved for treatm

266 Among patients treated with sofosbuvir and ledipasvir with or without GS-9669 or GS-9451, 100% (59/

267 Sofosbuvir and ledipasvir with ribavirin have high efficacy when taken

268 urse of sofosbuvir-velpatasvir or sofosbuvir-ledipasvir, with or without ribavirin.

269 eated with the combination of sofosbuvir and ledipasvir without ribavirin for 8 or 12 weeks.

270 tion who received 12 weeks of sofosbuvir and ledipasvir without ribavirin.

271 rect-acting antiviral drug to sofosbuvir and ledipasvir would allow a shorter treatment duration.